Serum Institute to double its investment in Biocon unit to $300 million
Serum Institute Life Sciences will now double its investment in Biocon Biologics from $150 million that was announced earlier in 2021 to $300 million.
Stay updated with breaking news from Biocon Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Serum Institute Life Sciences will now double its investment in Biocon Biologics from $150 million that was announced earlier in 2021 to $300 million.
Serum Institute of Life Sciences has announced to double up its investment in Biocon's unit to $300 million. With this, Biocon's unit will also get access to SILS' 100 million vaccine doses annually
Serum Life Sciences would make an additional equity investment of $150 million through the conversion of the $150 million loan provided to Biocon Pharma Limited.
This investment is in addition to the $ 150 million that SILS had invested in Biocon Biologics in November 2022, resulting in SILS’s aggregate equity investment in BBL amounting to $300 million.
Serum & Biocon Biologics agree to restructure equity investment